Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 6, 03 August 2023
Open
Access | Article
A review on the β-amyloid precipitation hypothesis
* Author to whom correspondence should be addressed.
Abstract
Alzheimer's disease (AD) is a well-known mental illness and memory loss is its most common symptom. Until now, the reason of AD has been an unsolved mystery, with the two most prominent previous hypotheses being β-amyloid deposition and Tau protein phosphorylation. However, this year, a seminal paper studying the β-amyloid precipitation hypothesis was found to be falsified, therefore, a large number of scientists have questioned the research value of this hypothesis. This paper is a review of the β-amyloid precipitation hypothesis. The development of β-amyloid precipitation hypothesis is described and previous studies on Aβ*56, Aβ42, and Aβ40 are reviewed. It is concluded that β-amyloid precipitation should continue to be studied. The author also argues that the falsification does not mean that the "amyloid" hypothesis is wrong; the only protein suspected of falsification is Aβ*56. The Aβ hypothesis can still be pursued because there are many other Aβ oligomers that have been shown to be neurotoxic.
Keywords
alzheimer's disease (AD), β-amyloid hypothesis, Aβ42, Aβ*56
References
1. Piller, C. Blots on a field?. Science (New York, N.Y.) 377(6604), 358–363 (2022). https://doi.org/10.1126/science.add9993.
2. Gurwitz, D. Auguste D and Alzheimer's disease. Lancet (London, England) 350(9073), 298 (1997). https://doi.org/10.1016/S0140-6736(05)62274-X.
3. Rodrigue, K.M., Kennedy, K.M., Park, D.C. Beta-Amyloid Deposition and the Aging Brain. Neuropsychol Rev 19, 436 (2009). https://doi.org/10.1007/s11065-009-9118-x.
4. Lesné, S., Koh, M., Kotilinek, L. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006). https://doi.org/10.1038/nature04533.
5. Qiu, T., Liu, Q., Chen, Y.X., Zhao, Y.F., Li, Y.M. Aβ42 and Aβ40: similarities and differences. J Pept Sci 21(7), 522-9 (2015). doi: 10.1002/psc.2789. Epub 2015 May 28. PMID: 26018760.
6. Steven, G. Younkin, The role of Aβ42 in Alzheimer's disease. Journal of Physiology-Paris 92(3–4), 289-292 (1998). https://doi.org/10.1016/S0928-4257(98)80035-1.
7. Amar, F., Sherman, M.A., Rush, T., Larson, M., Boyle, G., Chang, L., Götz, J., Buisson, A., Lesné, S.E. The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. Sci Signal 10(478), eaal2021 (2017). doi: 10.1126/scisignal.aal2021. PMID: 28487416; PMCID: PMC5859319.
8. Walsh, D.M., Selkoe, D.J. Aβ Oligomers – a decade of discovery. Journal of Neurochemistry 101, 1172-1184 (2007). https://doi.org/10.1111/j.14714159.2006.04426.x.
9. Jin, L., Wu, W.H., Li, Q.Y., Zhao, Y.F., Li, Y.M. Copper inducing Aβ42 rather than Aβ40 nanoscale oligomer formation is the key process for Aβneurotoxicity. Nanoscale 3, 4746–4751 (2011).
10. Chang, C.C., Althaus, J.C., Carruthers, C.J., Sutton, M.A., Steel, D.G., Gafni, A. Synergistic interactions between Alzheimer’s Aβ40 and Aβ42 on the surface of primary neurons revealed by single molecule microscopy. PLoS One 8, e82139 (2013).
11. Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D.W., Golde, T., McGowan, E. Aβ40 inhibits amyloid deposition in vivo. J. Neurosci 27, 627–633 (2007).
12. Humpel, C. Identifying and validating biomarkers for Alzheimer's disease. Trends in Biotechnology 29(1), 26-32 (2011). https://doi.org/10.1016/j.tibtech.2010.09.007.
13. Hansson, O., Lehmann, S., Otto, M. et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alz Res Therapy 11, 34 (2019). https://doi.org/10.1186/s13195-019-0485-0.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230161
- Copyright
- 03 August 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited